Relugolix NEW
| Price | $31 | $72 | $118 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Relugolix | CAS No.: 737789-87-6 |
| Purity: 99.67% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Relugolix |
| Description | Relugolix (RVT-601) is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (80.18 mM), Sonication is recommended. |
| Keywords | inhibit | Gonadotropin releasing hormone receptor | endometriosis | TAK 385 | GnRH Receptor | GnRH | prostate cancer | TAK385 | GNRHR | antagonistic | Inhibitor | RVT601 | uterine fibroid | FSH | Relugolix | RVT 601 |
| Inhibitors Related | Histrelin acetate | Cetrorelix Acetate | Deslorelin acetate(57773-65-6 free base) | Opigolix | Linzagolix choline | LGnRH-III, lamprey acetate(147859-97-0 free base) | Alarelin Acetate | Cetrorelix diacetate | Lecirelin acetate(61012-19-9 free base) | AG 045572 |
| Related Compound Libraries | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-12-30 | |
| $10.00/1KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-12-05 | |
| $0.00/1KG |
VIP1Y
|
Hangzhou Hyper Chemicals Limited
|
2024-09-06 | |
| $0.00/10mg |
VIP1Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2024-08-13 | |
| $0.10/1KG |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2024-08-05 | |
| $5.00/25kg |
Ouhuang Engineering Materials (Hubei) Co., Ltd
|
2024-04-25 | ||
| $1.00/1g |
VIP4Y
|
Dorne Chemical Technology co. LTD
|
2024-03-26 | |
| $0.00/1kg |
VIP2Y
|
Shandong Hanjiang Chemical Co., Ltd
|
2024-01-22 | |
| $0.00/1g |
Biopole Pharmatech Co., Ltd.
|
2024-01-19 | ||
| $0.00/25KG |
VIP5Y
|
Hebei Mujin Biotechnology Co.,Ltd
|
2023-08-14 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY